KR101454866B1 - 항암 약물로에 대한 무반응성 종양의 치료 및 화학증감을 위한 ｃｋ2 저해제의 용도 - Google Patents

항암 약물로에 대한 무반응성 종양의 치료 및 화학증감을 위한 ｃｋ2 저해제의 용도 Download PDF

Info

Publication number
KR101454866B1
KR101454866B1 KR1020087023587A KR20087023587A KR101454866B1 KR 101454866 B1 KR101454866 B1 KR 101454866B1 KR 1020087023587 A KR1020087023587 A KR 1020087023587A KR 20087023587 A KR20087023587 A KR 20087023587A KR 101454866 B1 KR101454866 B1 KR 101454866B1
Authority
KR
South Korea
Prior art keywords
cell proliferation
peptide
delete delete
drug
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020087023587A
Other languages
English (en)
Korean (ko)
Other versions
KR20090030251A (ko
Inventor
실비오 엘네스토 페레아 로드리구에스
야스셀 페레라 네그린
아리엘리스 로드리구에스 율로아
헤오바니스 길 발데스
야스셀 라모스 고메스
리라 로사 카스텔라노스 세르라
라사로 이람 베탄코유르트 누녜스
아니엘 산체스 푸엔테
호르게 페르난데스 데 코스시오 도르타 듀퀘
보리스 엘네스토 아세베도 카스트로
루이스 하비엘 곤잘레스 로페스
브라디미르 베사다 페레스
다니엘 페르난도 아론소
다니엘 에듀알도 고메스
Original Assignee
센트로 데 인제니에리아 제네티카 와이 바이오테크놀로지아
바이오렉 에스.아.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40134932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101454866(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 센트로 데 인제니에리아 제네티카 와이 바이오테크놀로지아, 바이오렉 에스.아. filed Critical 센트로 데 인제니에리아 제네티카 와이 바이오테크놀로지아
Publication of KR20090030251A publication Critical patent/KR20090030251A/ko
Application granted granted Critical
Publication of KR101454866B1 publication Critical patent/KR101454866B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020087023587A 2006-02-28 2007-02-28 항암 약물로에 대한 무반응성 종양의 치료 및 화학증감을 위한 ｃｋ2 저해제의 용도 Active KR101454866B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20060049A CU23511B6 (es) 2006-02-28 2006-02-28 Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
CU2006-0049 2006-02-28
PCT/CU2007/000010 WO2007098719A1 (es) 2006-02-28 2007-02-28 Combinación farmaceutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas

Publications (2)

Publication Number Publication Date
KR20090030251A KR20090030251A (ko) 2009-03-24
KR101454866B1 true KR101454866B1 (ko) 2014-11-04

Family

ID=40134932

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087023587A Active KR101454866B1 (ko) 2006-02-28 2007-02-28 항암 약물로에 대한 무반응성 종양의 치료 및 화학증감을 위한 ｃｋ2 저해제의 용도

Country Status (22)

Country Link
US (3) US8871725B2 (enExample)
EP (1) EP1997506B8 (enExample)
JP (2) JP5733880B2 (enExample)
KR (1) KR101454866B1 (enExample)
CN (1) CN101432012B (enExample)
AR (1) AR059645A1 (enExample)
AU (1) AU2007219572B2 (enExample)
BR (1) BRPI0708307B1 (enExample)
CA (1) CA2642943C (enExample)
CL (1) CL2015001086A1 (enExample)
CU (1) CU23511B6 (enExample)
CY (1) CY1114686T1 (enExample)
DO (1) DOP2007000040A (enExample)
MX (1) MX2008011141A (enExample)
MY (1) MY150135A (enExample)
NO (1) NO341904B1 (enExample)
PE (1) PE20081191A1 (enExample)
PL (1) PL1997506T3 (enExample)
RU (1) RU2396974C2 (enExample)
UY (1) UY30175A1 (enExample)
WO (1) WO2007098719A1 (enExample)
ZA (1) ZA200807323B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
KR20210079313A (ko) 2018-10-19 2021-06-29 센화 바이오사이언시즈 인코포레이티드 암 치료에서 면역 조절을 위한 조합
CN109875998B (zh) * 2019-01-24 2021-09-03 武汉大学 酰胺类生物碱在制备肿瘤化疗药物增敏剂中的应用及抗肿瘤药物组合物
CN110448699B (zh) * 2019-06-12 2022-03-11 天津医科大学 包含功能性多肽修饰七甲川花菁素类染料的肿瘤细胞核靶向载药纳米粒子及制备方法
CU20200103A7 (es) * 2020-12-18 2022-07-08 Ct Ingenieria Genetica Biotecnologia Péptido sintético para la inducción de inmunidad antitumoral y antiviral
CN114712377B (zh) * 2022-04-26 2023-08-15 江苏师范大学 断血流皂苷a在制造药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050002811A (ko) * 2001-12-20 2005-01-10 센트로 데 인제니에리아 제네티카 와이 바이오테크놀로지아 인간 유두종 바이러스 관련 암 및 기타 상피종양 치료용펩티드
WO2005056014A1 (en) * 2003-12-09 2005-06-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for suppressing an immune response or a treating a proliferative disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK284788B6 (sk) * 1996-10-15 2005-11-03 G. D. Searle & Co. Použitie inhibítorov cyklooxygenázy-2 pri liečení a prevencii neoplázie
JP2005533748A (ja) * 2002-03-08 2005-11-10 シグナル ファーマシューティカルズ，インコーポレイテッド 増殖性障害および癌を治療、予防、または管理するための併用療法
US20060014987A1 (en) * 2003-07-07 2006-01-19 Lan Huang Synthesis of beta-elemene, intermediates thereto, analogues and uses thereof
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050002811A (ko) * 2001-12-20 2005-01-10 센트로 데 인제니에리아 제네티카 와이 바이오테크놀로지아 인간 유두종 바이러스 관련 암 및 기타 상피종양 치료용펩티드
WO2005056014A1 (en) * 2003-12-09 2005-06-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for suppressing an immune response or a treating a proliferative disorder

Also Published As

Publication number Publication date
AU2007219572B2 (en) 2012-07-05
US9226946B2 (en) 2016-01-05
PL1997506T3 (pl) 2013-04-30
CN101432012A (zh) 2009-05-13
ZA200807323B (en) 2009-05-27
BRPI0708307B1 (pt) 2019-07-23
RU2008138534A (ru) 2010-04-10
WO2007098719A1 (es) 2007-09-07
CL2015001086A1 (es) 2016-05-13
PE20081191A1 (es) 2008-09-24
NO341904B1 (no) 2018-02-19
CU23511B6 (es) 2010-04-13
EP1997506B1 (en) 2012-12-05
EP1997506B8 (en) 2013-02-20
UY30175A1 (es) 2008-01-31
US20090130228A1 (en) 2009-05-21
DOP2007000040A (es) 2007-09-30
BRPI0708307B8 (enExample) 2021-05-25
CA2642943A1 (en) 2007-09-07
BRPI0708307A2 (pt) 2011-05-24
US20150111832A1 (en) 2015-04-23
NO20084119L (no) 2008-11-25
JP2013231065A (ja) 2013-11-14
US20150030700A1 (en) 2015-01-29
KR20090030251A (ko) 2009-03-24
CA2642943C (en) 2013-07-23
RU2396974C2 (ru) 2010-08-20
CN101432012B (zh) 2013-01-02
CY1114686T1 (el) 2016-10-05
HK1132451A1 (en) 2010-02-26
MY150135A (en) 2013-11-29
US9278118B2 (en) 2016-03-08
US8871725B2 (en) 2014-10-28
EP1997506A1 (en) 2008-12-03
MX2008011141A (es) 2009-01-26
JP5733880B2 (ja) 2015-06-10
JP2009528306A (ja) 2009-08-06
AR059645A1 (es) 2008-04-16
AU2007219572A1 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
US9226946B2 (en) Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs
Kim et al. Ubiquitin–proteasome system as a target for anticancer treatment—an update
US8691870B2 (en) Use of isothiocyanates for treating cancer
KR20140143166A (ko) 조합 요법에 의한 프로카스파제 ３ 활성화
CN102526022A (zh) 表没食子儿茶素没食子酸酯在制备抗肿瘤药物中的应用
JP2006503852A (ja) 抗癌薬としてのカスパーゼインヒビター
CN109310650A (zh) 用于减少过表达c-myc的癌症中的c-myc的化合物
CN104918630A (zh) 抗药性癌细胞的抑制
US8088822B2 (en) Use of fenretinide or bioactive derivatives thereof and pharmaceutical compositions comprising the same
CN113329772B (zh) 化学疗法与重组齐整小核菌凝集素的联合疗法
Hudson et al. Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes
Cortes et al. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies
CN112263578B (zh) Tipranavir在制备杀伤肿瘤干细胞和肿瘤细胞的癌症治疗药物中的用途
ES2398586T3 (es) Uso del inhibidor de CK2 para el tratamiento y la quimiosensibilización de tumores refractarios a fármacos anticancerosos
KR101316642B1 (ko) 메틸 피오포바이드를 유효성분으로 포함하는 항암제 내성 극복 의약 조성물
Suksamai Effect of 5-o-(n-boc-l-alanine)-renieramycin t in the suppression of lung cancer stem cells
CN118717739A (zh) 百菌清在制备用于诱导crbn底物泛素化降解的抗肿瘤药物中的应用
HK1132451B (en) Use of ck2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs
KR20060066610A (ko) Ａｍｐｋ의 활성 억제에 의한 항암제 약효의 증진 방법
Chen et al. The induction of orphan nuclear receptor Nur77 expression by n-butylenephthalide aspharmaceuticals on hepatocellular carcinoma (HCC) cells therapy
Bai et al. Design characterization and in vitro applications of novel chemotactic peptide-based drug delivery systems against cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080926

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120220

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131024

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140428

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131024

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140526

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140428

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20140717

Appeal identifier: 2014101003098

Request date: 20140526

E701 Decision to grant or registration of patent right
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140526

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140526

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20131219

Patent event code: PB09011R02I

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20140717

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20141013

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20141020

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20141021

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170912

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170912

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20180928

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20180928

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20190923

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190923

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20200921

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20210927

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20220818

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20230719

Start annual number: 10

End annual number: 10